Akebia Therapeutics, Inc. (NASDAQ: AKBA) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with kidney disease. The company’s primary research and development efforts center on treating anemia associated with chronic kidney disease (CKD) through the discovery of oral small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylase (HIF-PH). Akebia’s lead product candidate, vadadustat, is designed to stimulate erythropoiesis by stabilizing HIF, potentially offering an alternative to injectable therapies for anemia in dialysis and non-dialysis CKD patients.
Akebia has established strategic partnerships to advance its pipeline globally, most notably with Otsuka Pharmaceutical Co., Ltd., which holds co‐development and commercialization rights for vadadustat in select markets. Through these collaborations, Akebia seeks to leverage its scientific expertise and partner resources to conduct late-stage clinical trials, obtain regulatory approvals, and build a commercial infrastructure. The company also explores additional HIF-PH inhibitors and combination therapies aimed at improving outcomes in nephrology.
Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia went public in December 2014 to accelerate its research and development programs. Since its inception, the company has expanded its operations across North America, with research collaborations and clinical trial sites in Europe and Asia. Akebia’s management team comprises industry veterans in nephrology, drug development and regulatory affairs, guiding the company through clinical milestones and toward its goal of transforming care for kidney disease patients.
AI Generated. May Contain Errors.
Free AKBA Stock Alerts